LPA and CELA1

Number of citations of the paper that reports this interaction (PubMedID 9111002)
5

Data Source:
HPRD (in vitro)

		LPA	CELA1
Description		lipoprotein(a)	chymotrypsin like elastase 1
Image		No pdb structure	No pdb structure
GO Annotations	Cellular Component	Extracellular Region Plasma Lipoprotein Particle	Extracellular Space
	Molecular Function	Fibronectin Binding Serine-type Endopeptidase Activity Endopeptidase Inhibitor Activity Protein Binding Heparin Binding Apolipoprotein Binding	Serine-type Endopeptidase Activity Metal Ion Binding
	Biological Process	Proteolysis Lipid Metabolic Process Lipid Transport Blood Circulation Negative Regulation Of Endopeptidase Activity Low-density Lipoprotein Particle Remodeling	Negative Regulation Of Transcription By RNA Polymerase II Proteolysis Inflammatory Response Post-embryonic Development Wnt Signaling Pathway Exocrine Pancreas Development Multicellular Organism Growth Regulation Of Cell Proliferation Regulation Of Cell Differentiation Positive Regulation Of Angiogenesis Positive Regulation Of Transcription By RNA Polymerase II Tissue Remodeling Elastin Catabolic Process Pancreas Morphogenesis
Pathways
Drugs			N,N-dimethylformamide Para-Isopropylaniline Mdl 101,146 2-[5-Methanesulfonylamino-2-(4-Aminophenyl)-6-Oxo-1,6-Dihydro-1-Pyrimidinyl]-N-(3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl)Acetamide 2-[4-[[(S)-1-[[(S)-2-[[(Rs)-3,3,3-Trifluoro-1-Isopropyl-2-Oxopropyl]Aminocarbonyl]Pyrrolidin-1-Yl-]Carbonyl]-2-Methylpropyl]Aminocarbonyl]Benzoylamino]Acetic Acid (Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine N-[2-(1-Formyl-2-Methyl-Propyl)-1-(4-Piperidin-1-Yl-but-2-Enoyl)-Pyrrolidin-3-Yl]-Methanesulfonamide Freselestat (3R)-3-ethyl-N-[(4-methylphenyl)sulfonyl]-L-aspartic acid (TERT-BUTYLOXYCARBONYL)-ALANYL-AMINO ETHYL-FORMAMIDE (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE [1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE (2R)-3-{[(BENZYLAMINO)CARBONYL]AMINO}-2-HYDROXYPROPANOIC ACID 3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE (2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID (2S,3S)-3-FORMYL-2-({[(4-NITROPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID
Diseases
GWAS		Aortic valve stenosis ( 29511194) Aortic-valve calcification ( 23388002) Blood protein levels ( 28240269) Body mass index ( 26426971) Body mass index (age>50) ( 26426971) Body mass index x sex x age interaction (4df test) ( 26426971) Cholesterol, total ( 24097068 28270201 25961943 20686565) Coronary artery disease ( 29212778 24262325 30104761 26343387 28714974) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Coronary artery disease in diabetes ( 30003307) Coronary artery disease or ischemic stroke ( 24262325) Coronary artery disease or large artery stroke ( 24262325) Coronary heart disease ( 19198611 21378990) End stage renal disease x APOL1 genotype interaction ( 29885931) HDL cholesterol ( 25961943 20686565) HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Heart failure ( 31919418) Ischemic stroke (large artery atherosclerosis) ( 29531354) LDL cholesterol ( 24097068 30275531 25961943 20686565) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Lipid or lipoprotein levels ( 23696881) Lipoprotein (a) levels ( 26377243 30108283 28512139) Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention) ( 31186284) Lipoprotein phospholipase A2 activity in cardiovascular disease ( 28753643) Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms ( 28512139) Lipoprotein-associated phospholipase A2 activity change in response to statin therapy ( 23118302) Lp (a) levels ( 21900290 19124843) Medication use (agents acting on the renin-angiotensin system) ( 31015401) Medication use (antithrombotic agents) ( 31015401) Medication use (beta blocking agents) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (salicylic acid and derivatives) ( 31015401) Medication use (vasodilators used in cardiac diseases) ( 31015401) Metabolic syndrome ( 31589552) Metabolite levels (lipoprotein measures) ( 27005778) Minimum ankleâ€“brachial index ( 31285632) Monocyte early outgrowth colony forming units ( 21493818) Myocardial infarction ( 26343387) Parental lifespan ( 29030599) Parental longevity (both parents in top 10%) ( 29227965) Parental longevity (combined parental age at death) ( 29227965) Parental longevity (combined parental attained age, Martingale residuals) ( 29227965) Parental longevity (father's age at death) ( 31484785 29227965) Parental longevity (father's attained age) ( 29227965) Parental longevity (mother's age at death or mother's attained age) ( 31484785) Parental longevity (mother's age at death) ( 29227965) Parental longevity (mother's attained age) ( 29227965) Peripheral artery disease ( 31285632) Plasma plasminogen levels ( 25208887) Protein quantitative trait loci ( 18464913) Response to statin therapy ( 22368281) Response to statins (LDL cholesterol change) ( 25350695 22331829) Total cholesterol levels ( 28334899 30275531) Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Triglycerides ( 30275531 25961943)	Obesity-related traits ( 23251661)
Interacting Genes		9 interacting genes: APOH CANX CELA1 ELANE FBLN5 FGB FN1 LRP2 MMP12	6 interacting genes: A2M CSN2 LPA PI3 SERPINA1 SERPINA3
Entrez ID		4018	1990
HPRD ID		01063	00553
Ensembl ID		ENSG00000198670	ENSG00000139610
Uniprot IDs			Q9UNI1
PDB IDs
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?